Exploring Second-Line Treatments for PBC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

Now Viewing

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

EP: 11.Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

EP: 12.Long-Term Safety of Second-Line Therapies for PBC

EP: 13.Best Practices in Switching PBC Therapies

EP: 14.Monitoring Patients Transitioning From Obeticholic Acid

EP: 15.Additional Considerations With PBC Therapies

Video content above is prompted by the following:

How often do patients require second-line treatments for PBC, and what agents are available for second-line management?
How do the mechanisms of action differ between seladelpar, elafibranor, and obeticholic acid?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!